Human papillomavirus type 16 E7 oncoprotein-derived peptides presented on major histocompatibility complex class I (HPV16 E7-MHC I)

The HPV16 E7 oncoprotein-derived peptides presented on MHC class I represent a critical target for immunotherapy in HPV-associated cancers (PMID: 24191933). HPV16 E7 is a viral oncoprotein that promotes cell cycle progression and genomic instability by inactivating the retinoblastoma protein (pRb) (PMID: 10482232). Because E7 is constitutively expressed in HPV-transformed cells and absent in healthy tissues, its processed peptides presented on the cell surface via MHC class I molecules serve as highly specific "foreign" antigens (PMID: 32778778). Therapeutic strategies targeting this complex include therapeutic vaccines like ISA101 and PDS0101, which are designed to elicit endogenous T-cell responses (PMID: 30262526, PMID: 32434617). Additionally, adoptive cell therapies using T-cell receptors (TCRs) engineered to recognize specific E7 epitopes, such as the HLA-A*02:01-restricted E7 11-19 peptide, are in clinical development (PMID: 30531979). These approaches aim to trigger cytotoxic T-lymphocyte-mediated destruction of malignant cells while sparing normal tissue. The clinical success of these therapies often depends on the stable expression of MHC molecules, as HLA downregulation is a common mechanism of immune evasion in HPV-positive tumors (PMID: 26307133).

Other names

HPV16 E7 peptide-HLA complexHPV16 E7 antigenE7-MHC I complexHPV16 E7 11-19 peptide presented on HLA-A*02:01HPV16 E7 82-90 peptide presented on HLA-A*02:01

T-cell receptor (TCR) mediated recognition of the peptide-MHC complex leading to cytotoxic T-lymphocyte activation and tumor cell lysis.